Why the study?
Does a novel mitral valve plasty approach using 0.625% glutaraldehyde solution improve outcomes in patients with acute and active infective mitral valve endocarditis?
Does a novel mitral valve plasty approach using 0.625% glutaraldehyde solution improve outcomes in patients with acute and active infective mitral valve endocarditis?
The use of 0.625% glutaraldehyde solution during mitral valve repair for active infective endocarditis is feasible and associated with good mid-term survival and no recurrence of infection.
Supports feasibility of glutaraldehyde-assisted MVP in active endocarditis; hypothesis-generating and requires prospective trials before wider adoption.
BACKGROUND: The aim of this study was to review our experience of mitral valve (MV) repair for acute and active infective endocarditis (AAIE) and to identify the feasibility of a new approach together with the mid-term results. METHODS AND RESULTS: A retrospective analysis was performed on 35 consecutive AAIE patients surgically treated in the isolated mitral position. Mean follow-up after the surgery was 4.3±3.7 years. 30 of the 35 patients were successfully treated by MV plasty (MVP); however, MV replacement (MVR) was necessary in the remaining 5 patients. Our novel approach included resection of the infective lesion, approximation with direct suture and/or patch repair with bovine or autopericardium after 2-min treatment of it and the defective leaflet edge(s) with 0.625% glutaraldehyde solution, reconstruction with artificial chordae and ring annuloplasty. The success rate of MVP was 85.7%. The longest postoperative follow-up echocardiography showed no mitral regurgitation (MR) in 4, trivial MR in 4, mild MR in 16 and moderate MR in 5 patients in the MVP group. The 5-year survival rate in the MVP group was 89±6%. MVR was required in 1 patient 2 months after MVP because of increasing MR. Recurrence of endocarditis has not been observed in any case. CONCLUSIONS: Glutaraldehyde was safely used in a surgical intervention for AAIE in the mitral position with acceptable early and mid-term results.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: